Table 2.
Antibodies Used in the Characterization of SP in AD/Fl Patients
| Antibody | Epitope/marker | Type | Dilution | Antigen retrieval | Reference |
|---|---|---|---|---|---|
| 4G8 | Aβ residues 17–24 | IgG2b | 1:20,000 | Formic acid | Senetek, Maryland Heights, MO |
| 6E10 | Aβ N-terminus; recognizes Aβ 5–11 | IgG1 | 1:10,000 | Formic acid | Senetek |
| 6F3D | Aβ N-terminus | IgG1 | 1:25 | Formic acid | Dako, Glostrup, Denmark |
| JRF/AβN/11 | Aβ N-terminus | IgG2a | 1:500 | Formic acid | Gift from M. Mercken |
| JRF/cAb40/6 | Aβ40 | IgG2a | 1:500 | Formic acid | Gift from M. Mercken |
| R209 | Aβ40 | pAb-rabbit | 1:400 | Formic acid | Gift from P. Mehta |
| FCA3340 | Aβ40 | pAb-rabbit | 1:150 | Formic acid | Gift from F. Checkler |
| JRF/cAb42/12 | Aβ42 | IgG1 | 1:500 | Formic acid | Gift from M. Mercken |
| FCA3542 | Aβ42 | pAb-rabbit | 1:250 | Formic acid | Gift from F. Checkler |
| R226 | Aβ42 | pAb-rabbit | 1:400 | Formic acid | Gift from P. Mehta |
| AT8 | Abnormally phosphorylated tau | IgG1 | 1:20,000 | — | Gift from Innogenetics, Zwijraarde, Belgium |
| Anti-CD31 | Endothelium | IgG1 | 1:100 | Citrate buffer | JC70; Dako |
| Anti-CD34 | Endothelium | IgG1 | 1:100 | Citrate buffer | QBEnd/10; Dako |
| Anti-SMA | Smooth muscle cell actin | Citrate buffer | Dako | ||
| Anti-collagen type IV | Vascular basement membrane | IgG1 | 1:50 | Citrate buffer | Dako |
| Anti-GFAP | Glial fibrillary acidic protein | IgG1 | 1:1000 | Citrate buffer | Dako |
| Anti-CD68 | Macrophage | IgG3 | 1:100 | Pronase digestion | Dako |
| Anti-ubiquitin | Ubiquitin | pAb-rabbit | Citrate buffer | Dako | |
| Anti-C1q complement | Complement cascade | pAb-rabbit | 1:100 | Citrate buffer | Dako |
| Anti-HLA-DP,DQ,DR | Complement cascade | IgG1 | 1:100 | Citrate buffer | Dako |
| Anti-VEGF | Angiogenesis | pAb-goat | 1:100 | Citrate buffer | R&D Systems, Abingdon, UK |
| Anti-bFGF | Angiogenesis | pAb-goat | 1:100 | Citrate buffer | R&D Systems |